LEADER 01460nam  2200397 a 450 
001 9910697037703321
005 20230902162248.0
035   $a(CKB)5470000002384526
035   $a(OCoLC)609871343
035   $a(EXLCZ)995470000002384526
100   $a20100428d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBrand-name prescription drug pricing$b[electronic resource] $elack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases : report to congressionals requesters
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2009]
215   $a1 online resource (ii, 35 pages)
300   $aTitle from PDF title screen (GAO, viewed Apr. 27, 2010).
300   $a"December 2009."
300   $a"GAO-10-201."
320   $aIncludes bibliographical references.
517   $aBrand-name prescription drug pricing 
606   $aPrescription pricing
606   $aBrand name products$xPrices
606   $aPrescription pricing$xGovernment policy$zUnited States
615  0$aPrescription pricing.
615  0$aBrand name products$xPrices.
615  0$aPrescription pricing$xGovernment policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910697037703321
996   $aBrand-name prescription drug pricing$93519753
997   $aUNINA